Linalyl Acetate

Linalyl Acetate

SCHEMBL5773882

C=CC(C)(CCC=C(C)C)OC(C)=O.C=CC(C)(O)CCC=C(C)C

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 8/20 0.67
HIF1A Q16665 4/20 0.40
EPAS1 Q99814 4/20 0.40
CYP3A4 P08684 4/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.33
TRPC6 Q9Y210 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
MAPK1 P28482 2/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
CHRNA7 P36544 1/20 0.31
STAT3 P40763 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Linalyl Acetate SCHEMBL58028 0.92 ALOX15 (0.52) ALOX15HIF1AEPAS1CYP3A4LMNA
Linalyl Acetate SCHEMBL15745424 0.92 ALOX15 (0.52) ALOX15HIF1AEPAS1CYP3A4LMNA
Linalyl Acetate SCHEMBL15745425 0.92 ALOX15 (0.52) ALOX15HIF1AEPAS1CYP3A4LMNA
Linalyl Acetate SCHEMBL901206 0.92 ALOX15 (0.52) ALOX15HIF1AEPAS1CYP3A4LMNA
Linalyl Acetate SCHEMBL8141477 0.92 ALOX15 (0.56) ALOX15HIF1AEPAS1CYP3A4LMNA
Linalyl Acetate SCHEMBL4930354 0.89 ALOX15 (0.49) ALOX15HIF1AEPAS1CYP3A4LMNA
Linalyl Acetate SCHEMBL1234147 0.89 ALOX15 (0.59) ALOX15HIF1AEPAS1CYP3A4LMNA
Linalyl Acetate SCHEMBL8141476 0.86 ALOX15 (0.46) ALOX15HIF1AEPAS1CYP3A4LMNA
Linalyl Acetate SCHEMBL29127460 0.85 ALOX15 (0.45) ALOX15HIF1AEPAS1CYP3A4LMNA
Linalool SCHEMBL28023286 0.84 ALOX15 (0.76) ALOX15HIF1AEPAS1CYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210277328-A1 MUSK COMPOSITIONS AND METHODS OF USE THEREOF TAKASAGO INTERNATIONAL CORPORATION (JP) 2021-09-09 US claimed
EP-3111930-B1 COMPOSITION FOR TREATING DEPRESSION, BIPOLAR DISORDERS, RECURRENT MEDICAL DEPRESSIVE DISORDERS AND OTHER LONG-TERM AFFECTIVE DISORDERS BIERWIRTH ROLF (AT) 2018-04-18 EP claimed
US-20260108457-A1 THERMAL ENERGY SYSTEM FOR ADMINISTERING ACTIVE AGENTS ULTRAORAL LTD. (IL) 2026-04-23 US disclosed
CN-121041360-A Chinese herbal medicine agalloch eaglewood composition and preparation method thereof 江西德汇生物科技有限公司 2025-12-02 CN disclosed
WO-2025072501-A2 METHOD FOR CONVERTING FARNESYL PYROPHOSPHATE SYNTHASE INTO A GERANYL PYROPHOSPHATE SYNTHASE THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2025-04-03 WO disclosed
CN-116963738-A Luminol for the prevention and treatment of sequelae of SARS-CoV-2 infection 麦翠奥制药公司 2023-10-27 CN disclosed
CN-116888262-A Enzymes and methods for fermentative production of monoterpene esters 艾瑟拜奥尼克斯公司 2023-10-13 CN disclosed
WO-2017138003-A1 ANTIMICROBIAL PRESERVATIVE COMPOSITIONS SHARON LABORATORIES LTD. (IL) 2017-08-17 WO disclosed
EP-1613277-A1 FRAGANCED SOLID COSMETIC COMPOSITIONS BASED ON A DESTRUCTURIZED STARCH DELIVERY SYSTEM UNILEVER PLC (GB) 2006-01-11 EP disclosed
WO-2004089315-A1 FRAGANCED SOLID COSMETIC COMPOSITIONS BASED ON A DESTRUCTURIZED STARCH DELIVERY SYSTEM UNILEVER PLC (GB) 2004-10-21 WO disclosed
EP-1061890-A1 FRAGRANCED COSMETIC PRODUCT UNILEVER PLC (GB) 2000-12-27 EP disclosed
EP-0912686-A2 DETERGENT COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 1999-05-06 EP disclosed
EP-0912667-A2 DETERGENT COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 1999-05-06 EP disclosed
EP-0912692-A1 DETERGENT COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 1999-05-06 EP disclosed
WO-1997043388-A2 DETERGENT COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 1997-11-20 WO disclosed
WO-1997043389-A1 DETERGENT COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 1997-11-20 WO disclosed
WO-1997043364-A2 DETERGENT COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 1997-11-20 WO disclosed
WO-1991007875-A1 COMPOSITION FOR KILLING THE PARASITIC BEE MITE VARROA JACOBSONI PRIGLI MARIA (HU) 1991-06-13 WO disclosed
US-4347190-A ORGANOLEPTIC GIVAUDAN CORPORATION (US) 1982-08-31 US disclosed
US-4255337-A SUBSTITUTED HEXENYL TETRAHYDROFURAN GIVAUDAN CORPORATION (US) 1981-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260108457-A1 THERMAL ENERGY SYSTEM FOR ADMINISTERING ACTIVE AGENTS TAS2R4, TAS2R30, TAS2R31 ALOX15 4696/4885HIF1A 4688/4885EPAS1 4086/4885
US-20210277328-A1 MUSK COMPOSITIONS AND METHODS OF USE THEREOF MUSK, MSI2, SYMPK ALOX15 168/4885HIF1A 1200/4885EPAS1 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.